Article Text

Download PDFPDF
Prophylactic malaria chemoprevention reduces readmission and death rate in children previously admitted to hospital for treatment of severe anaemia
  1. Sarah Murphy
  1. Department of Paediatrics, Cork University Hospital, Cork, Ireland
  1. Correspondence to Dr Sarah Murphy, Department of Paediatrics, Cork University Hospital, Cork, Ireland T12 DFK4; murphysarah19{at}yahoo.com

Statistics from Altmetric.com

Study design: Multi-site, double-blind, randomised, placebo-controlled trial across Kenya and Uganda.

Allocation: 1:1 ratio to receive either postdischarge malaria chemoprevention or placebo. Randomisation was performed by a computer-generated randomisation schedule prepared by an independent statistician.

Patients: 1049 children, 524 in the chemoprevention group and 525 in the placebo group. Children were less than 5 years of age at time of enrolment. Children who had been admitted to hospital with severe anaemia and fulfilled the eligibility criteria underwent randomisation to enter the study. All children received a 3-day course of artemether-lumefantrine at the time of discharge. Those selected to partake in the study were enrolled 2 weeks after discharge from hospital.

Intervention: To receive a standard 3-day treatment course of dihydroartemisinin-piperaquine at 2, 6 and 10 weeks. The control group received a placebo …

View Full Text

Footnotes

  • Review of article Kwambai TK, Dhabangi A, Idro R et al. Malaria chemoprevention in the postdischarge management of severe anemia. N Engl J Med. 2020;383:2242–54.

  • Contributors SM wrote the abstract and commentary.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.